Patents by Inventor Han-Yi Hsieh
Han-Yi Hsieh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11793823Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R1, R2, R3, and R4 is OR5 or CH2OR5 and the other R1, R2, R3, and R4 each independently are halogen, OH, OR5, CH2OR5, CO2H, OC?OR6, (C?O)R6, R6, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).Type: GrantFiled: March 21, 2022Date of Patent: October 24, 2023Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Yi-Wen Mao, Lu-Ping Lu, Wei-Hua Chang, Han-Yi Hsieh, Jhe Wei Hu, Tsai-Miao Shih, ChanHui Huang
-
Patent number: 11779561Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 1, 2022Date of Patent: October 10, 2023Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Yi-Wen Mao, Lu-Ping Lu, Wei-Hua Chang, Han-Yi Hsieh, Jhe Wei Hu, Tsai-Miao Shih, ChanHui Huang
-
Publication number: 20230218623Abstract: A salt of a neuroceutical and of an acid, wherein the neuroceutical is a substituted benzodiazepine, a substituted benzothiazepine, a substituted pyridopyrimidines or a substituted amino-cyclohexaneacetic acid; and the acid is benzoic acid, nicotinic acid, pantothenic acid and tannic acid. The molar ratio of the neuroceutical and the acid in the salt ranges from about 6:1 to about 1:5. Also disclosed herein are compositions comprising the neuroceutical salt and therapeutic uses thereof for treating a central nervous system (CNS) disorder or a metabolic disorder associated with the CNS disorder.Type: ApplicationFiled: May 5, 2021Publication date: July 13, 2023Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh, Yi-Feng Huang, Hsin-Hsin Yang, Ming-Hong Chien, Han-Yi Hsieh, Wei-Hua Chang
-
Publication number: 20220273600Abstract: The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): in which R1, R2, and R3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R1, R2, and R3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).Type: ApplicationFiled: March 21, 2022Publication date: September 1, 2022Applicant: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Hsun Huang, Han-Yi Hsieh, Jing-Jia Huang, Ching-Cheng Wang
-
Publication number: 20220218730Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R1, R2, R3, and R4 is OR5 or CH2OR5 and the other R1, R2, R3, and R4 each independently are halogen, OH, OR5, CH2OR5, CO2H, OC?OR6, (C?O)R6, R6, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).Type: ApplicationFiled: March 21, 2022Publication date: July 14, 2022Inventors: Guochuan Emil Tsai, Yi-Wen Mao, Lu-Ping Lu, Wei-Hua Chang, Han-Yi Hsieh, Jhe Wei Hu, Tsai-Miao Shih, ChanHui Huang
-
Patent number: 11382924Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 16, 2021Date of Patent: July 12, 2022Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Yi-Wen Mao, Lu-Ping Lu, Wei-Hua Chang, Han-Yi Hsieh, Jhe Wei Hu, Tsai-Miao Shih, ChanHui Huang
-
Publication number: 20220152069Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 1, 2022Publication date: May 19, 2022Applicant: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Yi-Wen Mao, Lu-Ping Lu, Wei-Hua Chang, Han-Yi Hsieh, Jhe Wei Hu, Tsai-Miao Shih, ChanHui Huang
-
Patent number: 11278509Abstract: The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): in which R1, R2, and R3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R1, R2, and R3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).Type: GrantFiled: January 18, 2019Date of Patent: March 22, 2022Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Hsun Huang, Han-Yi Hsieh, Jing-Jia Huang, Ching-Cheng Wang
-
Publication number: 20220054516Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 16, 2021Publication date: February 24, 2022Inventors: Guochuan Emil Tsai, Yi-Wen Mao, Lu-Ping Lu, Wei-Hua Chang, Han-Yi Hsieh, Jhe Wei Hu, Tsai-Miao Shih, ChanHui Huang
-
Patent number: 11154531Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 8, 2020Date of Patent: October 26, 2021Assignee: SYNEURX INTERNATIONAL (TAIWAN) CORP.Inventors: Guochuan Emil Tsai, Yi-Wen Mao, Lu-Ping Lu, Wei-Hua Chang, Han-Yi Hsieh, Jhe Wei Hu, Tsai-Miao Shih, ChanHui Huang
-
Publication number: 20210251945Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 8, 2020Publication date: August 19, 2021Inventors: Guochuan Emil Tsai, Yi-Wen Mao, Lu-Ping Lu, Wei-Hua Chang, Han-Yi Hsieh, Jhe Wei Hu, Tsai-Miao Shih, ChanHui Huang
-
Publication number: 20190151272Abstract: The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): in which R1, R2, and R3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R1, R2, and R3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).Type: ApplicationFiled: January 18, 2019Publication date: May 23, 2019Applicant: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Hsun Huang, Han-Yi Hsieh, Jing-Jia Huang, Ching-Cheng Wang
-
Patent number: 10226442Abstract: The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): in which R1, R2, and R3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R1, R2, and R3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).Type: GrantFiled: July 10, 2017Date of Patent: March 12, 2019Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Hsun Huang, Han-Yi Hsieh, Jing-Jia Huang, Ching-Cheng Wang
-
Publication number: 20190008813Abstract: The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): in which R1, R2, and R3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R1, R2, and R3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).Type: ApplicationFiled: July 10, 2017Publication date: January 10, 2019Inventors: Guochuan Emil Tsai, Ching-Hsun Huang, Han-Yi Hsieh, Jing-Jia Huang, Ching-Cheng Wang